--- title: "PepTracker Pro | Peptide Research & Education" url: https://peptrackerpro.com/ description: "Explore peptides, understand the science, and track your research. Educational information backed by citations." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) # Your Guide to Peptide Research Explore peptides, understand the science, and make informed decisions. Educational information backed by research citations. Start Here: https://peptrackerpro.com/start Open the App: https://app.peptrackerpro.com/ ## How PepTracker Pro Works ### Research Browse our peptide directory with detailed overviews, evidence ratings, and safety information. ### Compare Select up to 4 peptides and compare them side-by-side on key factors. ### Track Use the free PepTracker Pro app to log your peptide stack, set dosing reminders, and keep organized research notes — all in one place. Free App ## Featured Peptides View all (https://peptrackerpro.com/peptides) ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/5-amino-1mq \+ Compare: https://peptrackerpro.com/compare?select=5-amino-1mq Track in App: https://app.peptrackerpro.com/?add=5-amino-1mq ### Abaloparatide High Evidence Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label. Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/abaloparatide \+ Compare: https://peptrackerpro.com/compare?select=abaloparatide Track in App: https://app.peptrackerpro.com/?add=abaloparatide ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### AI-Discovered Antimicrobial Peptides Medium Evidence A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens. Antimicrobial: https://peptrackerpro.com/benefits/antimicrobial View Details: https://peptrackerpro.com/peptides/ai-antimicrobial-peptides \+ Compare: https://peptrackerpro.com/compare?select=ai-antimicrobial-peptides Track in App: https://app.peptrackerpro.com/?add=ai-antimicrobial-peptides ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-100 \+ Compare: https://peptrackerpro.com/compare?select=alv-100 Track in App: https://app.peptrackerpro.com/?add=alv-100 ## The app does what the website can't ### Dosing Reminders Set custom schedules and get notified ### Research Log Keep timestamped notes tied to each peptide ### Stack Management Track everything you're running in one dashboard Open the Free App: https://app.peptrackerpro.com/ 49 Peptides Profiled 80+ Glossary Terms 100% Free to Use ## Browse by Benefit Sleep: https://peptrackerpro.com/benefits/sleep Recovery: https://peptrackerpro.com/benefits/recovery Cognition: https://peptrackerpro.com/benefits/cognition Metabolism: https://peptrackerpro.com/benefits/metabolism Skin: https://peptrackerpro.com/benefits/skin Inflammation: https://peptrackerpro.com/benefits/inflammation Longevity: https://peptrackerpro.com/benefits/longevity Mood: https://peptrackerpro.com/benefits/mood Immune Support: https://peptrackerpro.com/benefits/immune-support Sexual Health: https://peptrackerpro.com/benefits/sexual-health Gut Health: https://peptrackerpro.com/benefits/gut-health Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth ## From the Blog All posts (https://peptrackerpro.com/blog) Research & Compounds cover image (https://peptrackerpro.com/blog/sebetralstat-ekterly-kvd900-kalvista-first-oral-on-demand-plasma-kallikrein-inhibitor-hereditary-angioedema-hae-acute-attack-treatment-bradykinin-kallikrein-kinin-contact-system-konfident-phase-3-nct05259917-konfident-s-konfident-kid-pediatric-fda-approved-october-1-2026) Research & Compounds ### Sebetralstat (Ekterly): The First Oral On-Demand Treatment for Hereditary Angioedema Attacks (October 2026 Update) (https://peptrackerpro.com/blog/sebetralstat-ekterly-kvd900-kalvista-first-oral-on-demand-plasma-kallikrein-inhibitor-hereditary-angioedema-hae-acute-attack-treatment-bradykinin-kallikrein-kinin-contact-system-konfident-phase-3-nct05259917-konfident-s-konfident-kid-pediatric-fda-approved-october-1-2026) Sebetralstat is the first pill that can stop a hereditary angioedema attack on demand. An oral plasma kallikrein inhibitor, it cut the median time to symptom relief to under two hours versus nearly seven on placebo - and in 2026 it posted positive pediatric data and a first-line guideline nod. Here is how it works, what KONFIDENT showed, and how it fits the HAE toolkit. PepTracker Pro Team October 1, 2026 9 min read Read (https://peptrackerpro.com/blog/sebetralstat-ekterly-kvd900-kalvista-first-oral-on-demand-plasma-kallikrein-inhibitor-hereditary-angioedema-hae-acute-attack-treatment-bradykinin-kallikrein-kinin-contact-system-konfident-phase-3-nct05259917-konfident-s-konfident-kid-pediatric-fda-approved-october-1-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/garadacimab-andembry-garadacimab-gxii-csl312-csl-behring-first-in-class-anti-activated-factor-xiia-fxiia-monoclonal-antibody-hereditary-angioedema-hae-prophylaxis-contact-system-kallikrein-bradykinin-vanguard-phase-3-nct04656418-once-monthly-subcutaneous-pediatric-september-30-2026) Research & Compounds ### Garadacimab (Andembry): The First-in-Class Factor XIIa Inhibitor for Preventing Hereditary Angioedema Attacks (September 2026 Update) (https://peptrackerpro.com/blog/garadacimab-andembry-garadacimab-gxii-csl312-csl-behring-first-in-class-anti-activated-factor-xiia-fxiia-monoclonal-antibody-hereditary-angioedema-hae-prophylaxis-contact-system-kallikrein-bradykinin-vanguard-phase-3-nct04656418-once-monthly-subcutaneous-pediatric-september-30-2026) Garadacimab is the first HAE prevention drug to switch off the swelling cascade at its very first step. A once-monthly antibody against activated Factor XII, it cut monthly attacks by ~89% versus placebo and left 62% of patients attack-free - and in July 2026 it posted positive results in children. Here is how it works, what the data show, and how it compares to the rest of the HAE toolkit. PepTracker Pro Team September 30, 2026 9 min read Read (https://peptrackerpro.com/blog/garadacimab-andembry-garadacimab-gxii-csl312-csl-behring-first-in-class-anti-activated-factor-xiia-fxiia-monoclonal-antibody-hereditary-angioedema-hae-prophylaxis-contact-system-kallikrein-bradykinin-vanguard-phase-3-nct04656418-once-monthly-subcutaneous-pediatric-september-30-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/atacicept-trutakna-taci-fc-fusion-protein-dual-baff-april-inhibitor-vera-therapeutics-iga-nephropathy-igan-origin-3-phase-3-nct04716231-proteinuria-upcr-gd-iga1-hematuria-egfr-fda-accelerated-approval-once-weekly-subcutaneous-september-29-2026) Research & Compounds ### Atacicept (Trutakna): The First Dual BAFF/APRIL Inhibitor Approved for IgA Nephropathy (September 29, 2026) (https://peptrackerpro.com/blog/atacicept-trutakna-taci-fc-fusion-protein-dual-baff-april-inhibitor-vera-therapeutics-iga-nephropathy-igan-origin-3-phase-3-nct04716231-proteinuria-upcr-gd-iga1-hematuria-egfr-fda-accelerated-approval-once-weekly-subcutaneous-september-29-2026) Atacicept spent two decades looking for the right disease - it failed in multiple sclerosis and stumbled in lupus. In IgA nephropathy it finally found its footing: on July 7, 2026 the FDA approved it as Trutakna, the first dual BAFF/APRIL inhibitor for the disease, after a Phase 3 trial cut proteinuria 42% versus placebo. Here's how it works, what the data show, and the accelerated-approval asterisk. PepTracker Pro Team September 29, 2026 9 min read Read (https://peptrackerpro.com/blog/atacicept-trutakna-taci-fc-fusion-protein-dual-baff-april-inhibitor-vera-therapeutics-iga-nephropathy-igan-origin-3-phase-3-nct04716231-proteinuria-upcr-gd-iga1-hematuria-egfr-fda-accelerated-approval-once-weekly-subcutaneous-september-29-2026) ## Stay Informed Get weekly peptide research summaries and new peptide profiles. ## Track Your Research with PepTracker Pro Save peptides, log your stack, and set reminders — all in the free PepTracker Pro app. Private | Mobile-First | Offline Access Try the Free App →: https://app.peptrackerpro.com/ Learn More: https://peptrackerpro.com/start ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "WebSite", "url": "https://peptrackerpro.com", "potentialAction": { "@type": "SearchAction", "target": { "@type": "EntryPoint", "urlTemplate": "https://peptrackerpro.com/peptides?q={search_term_string}" }, "query-input": "required name=search_term_string" } }, { "@context": "https://schema.org", "@type": "SoftwareApplication", "name": "PepTracker Pro", "applicationCategory": "HealthApplication", "operatingSystem": "Web", "url": "https://peptrackerpro.com", "description": "Educational peptide research tracker and comparison tool.", "offers": { "@type": "Offer", "price": "0", "priceCurrency": "USD" } } ] ```